# BioMime Vs. Xience Randomised Control Clinical Study

Study · id `cardio:ct-nct02112981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02112981](<https://clinicaltrials.gov/study/NCT02112981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02112981

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 256 participants.

## Technical summary

Registry record NCT02112981. Randomized; no masking; primary purpose treatment. Start 2014-11-05 (actual); primary completion 2017-09-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT02112981, source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)
- Started: 2014-11-05 (actual) (ClinicalTrials.gov record NCT02112981, source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)
- Primary completion: 2017-09-06 (actual) (ClinicalTrials.gov record NCT02112981, source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)
- Completion: 2019-12-01 (anticipated) (ClinicalTrials.gov record NCT02112981, source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)
- Countries: Belgium; Brazil; Czechia; Latvia; Netherlands; North Macedonia; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT02112981, source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02112981-2018-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: BioMime Vs. Xience Randomised Control Clinical Study
- Acronym: meriT-V
- Condition: Coronary Artery Disease
- Intervention (Device): Sirolimus Eluting Coronary Stent
- Intervention (Device): Everolimus-eluting Coronary stent
- Lead sponsor: Meril Life Sciences Pvt. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Meril Life Sciences Pvt. Ltd. (`cardio:org-meril-life-sciences-pvt-ltd`)

## Provenance

Content hash: 297aedd4742197b08c058eb92333647f8ae1e6c7eb84ed4d09125022c881ca9f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
